Navigation Links
Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results
Date:10/1/2009

FARMINGDALE, N.Y., Oct. 1 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, reported financial results for the fourth quarter and fiscal year ended June 30, 2009.

The Company also reported the following financial and operational achievements:

  • A cash payment of $3.5 million was received on April 7, 2009 from the sale of its Ultrasonics Laboratory Products business. Current and prior period results and the gain on the sale of the Ultrasonic Laboratory Products business are reported in the Company's financial statement as discontinued operations
  • Launched two new products into multi-billion dollar market segments
  • Launched a direct sales force in the U.S. for the SonicOne® Wound Cleansing and Debridement System
  • Added 14 new international distributors
  • Reduced inventories by 44% to $6.6 million as of June 30, 2009
  • Reduced accounts payable and accrued expenses and other current liabilities by 37% to $6.5 million
  • Reduced general and administrative expenses by 14% to $9.0 million as of June 30, 2009
  • On August 5, 2009 closed the transaction for the sale of Labcaire Systems, Ltd. to Puricore for up to $5.6 million and is reported as a subsequent event

Revenues for the fourth fiscal quarter ending June 30, 2009 were $10.5 million compared to $10.6 million for the three months ended June 30, 2008. The results reflect only continuing operations as of June 30, 2009 and 2008 as discontinued operations are excluded from such results. Discontinued operations represent the results of and the gain from the sale of the Ultrasonic Laboratory Products business. Revenues were adversely impa
'/>"/>

SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Spherix Reports Second Quarter Earnings
4. Tapestry Reports Second Quarter 2007 Results
5. Callisto Reports on Second-Quarter 2007 Milestones
6. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
7. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
8. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
9. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
10. Biopure Reports on Meeting with the FDA
11. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... OBP Medical Inc. declares victory in the battle ... hospitals. ,, Doctors at Newton-Wellesley Hospital in Newton, ... Medical,s Under Johnnies(TM) on patients, comfort and satisfaction ... is comparing patients, perception of comfort, privacy and ... Johnnies(TM) against the traditional hospital gown and socks. ...
(Date:12/14/2009)... Dec. 14 Embarrassing and sometimes uncomfortable colonoscopies ... National researchers are taking note of a new screening ... process. The Knoxville-based company, EDP Biotech Corporation ... ColoMarker, an affordable medical device doctors can use to ... "When you consider that 30% of colon cancer ...
(Date:12/14/2009)... 14 The board of directors of Eli ... declared a dividend for the first quarter of 2010 ... ,, The dividend is payable March 10, 2010 ... on ,, February 12, 2010. ,, Lilly, a ... pharmaceutical products by applying the latest research from its ...
Breaking Medicine Technology:Under Johnnies(TM) Proven To Increase Patient Satisfaction by OBP Medical Inc. 2EDP Biotech Takes Next Step in the Development of ColoMarker 2EDP Biotech Takes Next Step in the Development of ColoMarker 3China Sky One Medical Inc Announces Record Second Quarter 2009 Results 13565 1China Sky One Medical Inc Announces Record Second Quarter 2009 Results 13565 2China Sky One Medical Inc Announces Record Second Quarter 2009 Results 13565 3China Sky One Medical Inc Announces Record Second Quarter 2009 Results 13565 4China Sky One Medical Inc Announces Record Second Quarter 2009 Results 13565 5China Sky One Medical Inc Announces Record Second Quarter 2009 Results 13565 6China Sky One Medical Inc Announces Record Second Quarter 2009 Results 13565 7China Sky One Medical Inc Announces Record Second Quarter 2009 Results 13565 8China Sky One Medical Inc Announces Record Second Quarter 2009 Results 13565 9China Sky One Medical Inc Announces Record Second Quarter 2009 Results 13565 10China Sky One Medical Inc Announces Record Second Quarter 2009 Results 13565 11Miami Health Insurance Outlook and Update 54523 1Miami Health Insurance Outlook and Update 54523 2Miami Health Insurance Outlook and Update 54523 3Video 3A Schering Plough Announces FDA Approval of SAPHRIS 28R 29 28asenapine 29 for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Ep 54521 1Video 3A Schering Plough Announces FDA Approval of SAPHRIS 28R 29 28asenapine 29 for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Ep 54521 2Video 3A Schering Plough Announces FDA Approval of SAPHRIS 28R 29 28asenapine 29 for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Ep 54521 3Video 3A Schering Plough Announces FDA Approval of SAPHRIS 28R 29 28asenapine 29 for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Ep 54521 4Video 3A Schering Plough Announces FDA Approval of SAPHRIS 28R 29 28asenapine 29 for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Ep 54521 5Video 3A Schering Plough Announces FDA Approval of SAPHRIS 28R 29 28asenapine 29 for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Ep 54521 6Video 3A Schering Plough Announces FDA Approval of SAPHRIS 28R 29 28asenapine 29 for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Ep 54521 7Video 3A Schering Plough Announces FDA Approval of SAPHRIS 28R 29 28asenapine 29 for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Ep 54521 8
... Vical Incorporated (Nasdaq:,VICL) today reported financial results for ... quarter of 2007 were $3.1 million, compared with,revenues of ... net loss for,the second quarter of 2007 was $8.2 ... of $3.2 million, or $0.11 per share, for the ...
... Progression Rates Are the ... Resources, WALTHAM, Mass., Aug. 7 Decision ... advisory firms focusing on pharmaceutical,and healthcare issues, finds ... Sutent as the clinical gold standard for,the treatment ...
Other Medicine Technology:Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 2Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 3Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 4Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 5Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 6Wyeth's Torisel and Roche/Genentech's Avastin Will Challenge Pfizer's Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma 2
(Date:12/14/2009)... and more… , ... Santa Barbara, ... with scientists at University of Michigan, have developed synthetic particles ... red blood cells, including softness, flexibility, and the ability to ... of natural red blood cells is to carry oxygen, and ...
(Date:12/14/2009)... -- Americold Realty Trust ("Americold") announced today that it ... the U.S. Securities and Exchange Commission (the "SEC") relating ... shares. The number of shares to be offered and ... been determined. The common shares to be sold in ... ,, The joint book-running managers of the offering ...
(Date:12/14/2009)... Organization for Rare Disorders (NORD) today called upon Congress ... health insurance caps. In a full-page ad in ... Capitol Hill, NORD said the current Senate health reform ... for most Americans, contrary to what many people believe. ... the promises made by President Obama and Congress to ...
(Date:12/14/2009)... replaced tube watching , , MONDAY, Dec. 14 (HealthDay News) ... of television a week until he enrolled in a ... in half. , During his enforced period of deprivation, ... necessarily through strenuous exercise, although he did find his ... was spent reading and working on the computer, said ...
(Date:12/14/2009)... Ohio, Dec. 14 Skilled nursing facilities (SNFs) ... services in order to deal with a 92 percent ... fee) from $6.25 to $12.01 per bed per day, ... the average facility will pay an additional $17,520 to ... a total tax of $438,365 yearly. ,, Nearly 96 ...
Breaking Medicine News(10 mins):Health News:Synthetic Red Blood Cells Developed 2Health News:Synthetic Red Blood Cells Developed 3Health News:Americold Realty Trust Files Registration Statement for Proposed Initial Public Offering 2Health News:NORD Calls for Immediate End to Lifetime Insurance Caps 2Health News:Cutting TV Time Burns More Calories 2Health News:Survey Shows Tax Increase Forcing Ohio Skilled Nursing Facilities to Make Cuts 2Health News:Survey Shows Tax Increase Forcing Ohio Skilled Nursing Facilities to Make Cuts 3
... Journal of Occupational and Environmental Medicine, Investigates Relationship of Co-payments, ... ... Utilization, PHILADELPHIA, May 12 High prescription drug,co-payments are ... to a new study published this month in the,Journal of ...
... it has long been known that embryonic stem cells ... tissue-specific cells, the exact mechanism as to how this ... the Hebrew University of Jerusalem and elsewhere have succeeded ... as to whether the stem cells achieve their development ...
... think before they drink as part of a research project ... of health psychologists at The University of Nottingham plan to ... health effects of binge drinking and asking employees for a ... single session could change peoples binge drinking behaviour in the ...
... ULURU Inc. (Amex: ULU ),today reported financial results ... the quarter ended March 31, 2008, the net loss ... compared to a net,loss of $847,000, or $0.01 per ... 2008 net loss was impacted by non-cash expenses of,$497,000, ...
... mutated gene has been discovered as the key behind ... new research at Adelaides Womens & Childrens Hospital and ... published today in Nature Genetics, shows that although men ... The research has been led by Dr Leanne Dibbens ...
... look more attractive. Fish diet to avoid being beaten ... eaten as a result. , That is the fascinating conclusion ... the ARC Centre of Excellence for Coral Reef Studies and ... , The same team who recently revealed fish use the ...
Other Medicine News:Health News:New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health 2Health News:New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health 3Health News:New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health 4Health News:New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health 5Health News:How embryonic stem cells develop into tissue-specific cells demonstrated 2Health News:Think before you drink, says university research 2Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 2Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 3Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 4Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 5Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 6Health News:Mutant gene causes epilepsy, intellectual disability in women 2Health News:Fish diet to avoid fights 2
Flat tip, bare fiber, no cooling, polished SMA 905, 3 meters long. Sold in boxes of five. Each part is individually packaged in sterile Tyvek bags....
... unique lateral fiber possessing a ... rotated to any one of ... fibers in one. The fiber ... and coagulation and back to ...
... Ultrafin™ Stirrup is the latest ... stirrup features a roomier boot ... up to an 800 pound ... to position heavy legs more ...
... assist stirrups are designed to travel a full ... They lock tight wherever you release the rotating ... are done at the handle with no need ... socket. The rotation of system was designed to ...
Medicine Products: